Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Affiliations

• ¹ CHU de Montpellier, Hôpital St Eloi, Montpellier, France. l-vincent@chu-montpellier.fr.
• ² EBMT Statistical Unit, Leiden, The Netherlands.
• ³ CHU de Montpellier, Hôpital St Eloi, Montpellier, France.
• ⁴ University of Freiburg, Freiburg, Germany.
• ⁵ University Hospital of Basel, Basel, Switzerland.
• ⁶ Hôpital St Louis, Paris, France.
• ⁷ Barcelona Hospital Clinic, Barcelona, Spain.
• ⁸ University Medical Center Utrecht, Utrecht, Netherlands.
• ⁹ University Hospital Carl Gustav Carus, Dresden, Germany.
• ¹⁰ University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
• ¹¹ Klinikum Chemnitz, Chemnitz, Germany.
• ¹² Centre Henri Becquerel, Rouen, France.
• ¹³ Hôpital Haut-Levèque, Pessac, France.
• ¹⁴ Hannover Medical School, Hannover, Germany.
• ¹⁵ CHU Lyon Sud, Pierre-Benite, France.
• ¹⁶ Hospital Universitari I politècnic La Fe, Valencia, Spain.
• ¹⁷ Antwerp University Hospital (UZA), Antwerp-Edegem, Belgium.
• ¹⁸ Rambam Medical Center, Haifa, Israel.
• ¹⁹ A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
• ²⁰ EBMT Data Office, Leiden, UK.
• ²¹ Leiden University Medical Center, Leiden, The Netherlands.
• ²² St. James Hospital, Trinity College Dublin, Dublin, Ireland.
• ²³ University of Heidelberg, Heidelberg, Germany.
• ²⁴ CHU de Lille, Université de Lille, INSERM U1286, Infinite, Lille, France.
• ²⁵ Ankara University Faculty of Medicine, Ankara, Turkey.